

# Efficacy of Progesterone Receptor Antagonist for Treatment of Pyometra in Bitches

Upasana Chandrakar, Rajendra P. Tiwari, Mahesh R. Poyam, Girish K. Mishra\*

## ABSTRACT

The present study aimed to assess the efficacy of Progesterone Receptor Antagonist for Treatment of Pyometra in Bitches. The present research work was carried out on a total of 12 bitches diagnosed with pyometra. The animals were randomly assigned to two treatment protocols, with 6 animals in each group. In Group I, bitches were administered only with supportive therapies, i.e. fluid therapy, cloprostenol, and ceftriaxone. In Group II, bitches were administered with progesterone receptor antagonist (mifepristone) and supportive fluid therapy as in Gr-I. The physiological, hematological, and biochemical parameters were evaluated on days 0, 4<sup>th</sup>, and 8<sup>th</sup> of treatment. The recovery rate of treated bitches was assessed by ultrasonography post-treatment. There was a significant increase in the mean PCV and a decrease in leucocyte count in group II on day 8. After treatment, the mean serum globulin and creatinine level reduction was significant ( $p < 0.05$ ) in group II than group I. The mean serum ALT concentration in bitches with pyometra in different groups pre-treatment, during, and post-treatment were within the normal physiological range (10-94 U/L). The mean concentration of serum ALP decreased significantly ( $p < 0.05$ ) in both groups on day 8. The ultrasound examination on day 8 post-treatment revealed a reduction in uterine lumen, the thickness of the uterine wall, and decreased echogenicity indicative of treatment response in both groups. Bitches treated with progesterone receptor antagonist (mifepristone, Group-II) showed higher recovery (100 vs. 50%) and lower recurrence (17 vs. 67%) than Group I. From the present findings, it could be concluded that progesterone receptor antagonist proves to be a safe and efficient drug for the treatment of pyometra in bitches.

**Keywords:** Bitch, Mifepristone, Prostaglandin, Pyometra.

*Ind J Vet Sci and Biotech* (2021): 10.21887/ijvsbt.17.4.9

## INTRODUCTION

Pyometra or chronic purulent endometritis is a common metestral disease mainly affecting bitches over 8 years of age (Hadiya *et al.*, 2020; Singh *et al.*, 2020<sup>a</sup>). The pathogenesis of pyometra is primarily a hormonal imbalance or abnormal response to normal concentrations of estrogens and progesterone that affects the epithelial cells of the uterus and facilitates bacterial adherence, colonization, and growth (Noakes *et al.*, 2001). Progesterone results in endometrial proliferation and uterine glandular secretion, decreased myometrial contraction, closure of the cervix, and support to bacterial infection (Smith, 2006). The effective treatment of pyometra is an ovario-hysterectomy, as it removes discomfort from the distended uterus and sources of endotoxin (Rootwelt-Andersen and Farstad, 2006). In the absence of life-threatening signs, pyometra can be treated medically invaluable bitches to restore fertility (Melandri *et al.*, 2019). Repeated administration of PGF<sub>2α</sub> is indicated for metritis or open pyometra in healthy young bitches, which causes luteolysis and thus reduces plasma progesterone concentrations. Prostaglandins, however produce substantial adverse effects on the health and life of the animal. Antiprogestins are synthetic steroids that bind with great affinity to progesterone receptors without any effects of progesterone (Hoffmann *et al.*, 2000). Progesterone blockers are suggested to be beneficial for the treatment of closed pyometra in canines. Using an antiprogestin (aglepristone) in

Department of Veterinary Gynaecology and Obstetrics, College of Veterinary Science and Animal Husbandry, Anjora, Dau Shri Vasudev Chandrakar Kamdhenu Vishwavidyalaya, Durg, Chhattisgarh, India

**Corresponding Author:** Girish K. Mishra, Department of Veterinary Gynaecology and Obstetrics, College of Veterinary Science and Animal Husbandry, Anjora, Dau Shri Vasudev Chandrakar Kamdhenu Vishwavidyalaya, Durg, Chhattisgarh, India, e-mail: drkodu@gmail.com

**How to cite this article:** Chandrakar, U., Tiwari, R.P., Poyam, M.R., Mishra, G.K. (2021). Efficacy of Progesterone Receptor Antagonist for Treatment of Pyometra in Bitches. *Ind J Vet Sci and Biotech*, 17(4), 41-45.

**Source of support:** Nil

**Conflict of interest:** None.

**Submitted:** 29/02/2021 **Accepted:** 15/07/2021 **Published:** 10/10/2021

combination with PGF<sub>2α</sub> was highly successful (Fieni, 2006). Mifepristone has five times greater relative binding affinity than progesterone for progesterone receptors thus, mimicking the effects observed during luteolysis, leading to relaxation of the cervix (Verstegen *et al.*, 2008). The present study was aimed to evaluate the effect of progesterone receptor antagonists in the treatment of canine pyometra.

## MATERIALS AND METHODS

The study was conducted on 12 clinical pyometra cases in bitches, irrespective of their age, breed, and parity. They were

presented at the Department of Veterinary Gynaecology and Obstetrics and Veterinary Clinical Complex, College of Veterinary Science & AH, Anjora, Durg, Chhattisgarh. Clinical and ultrasonographic (Prosound 2 ALOKA) examination was carried out for confirmation of pyometra. Ultrasonography revealed an enlarged lumen of both the uterine horns with the hyperechoic bands pocket and the appearance of intraluminal anechoic to hypoechogenicity for the thickened uterine wall. The affected bitches were randomly divided into two equal groups with six animals in each. The bitches in group I (Control or standard treatment) were administered with supportive fluid therapy along with cloprostenol 5 µg/kg b.wt. on day 1, 2 and 6<sup>th</sup> i/m and ceftriaxone @ 20 mg/kg b.wt. i/v daily for 5 days. Group II (test treatment) bitches were administered with progesterone receptor antagonist (mifepristone) @ 5 mg/kg b.wt. Orally on 1, 2, 3, and on 7<sup>th</sup> day along with supportive fluid therapy with cloprostenol and ceftriaxone as in Group I.

Bitches with pyometra were subjected to ultrasonography on day 0 (pre-treatment), day 4<sup>th</sup> (during treatment) and day 8<sup>th</sup> (post-treatment) using 2.5 to 5 MHz trans-abdominal probes. The clinical parameters, rectal temperature, respiratory rate, and heart rate were recorded in all the animals. 2 mL of blood was collected on days 0, 4<sup>th</sup>, and 8<sup>th</sup> from a cephalic vein in EDTA vials for hematology, and 5 mL of blood was collected in vials without anticoagulant for serum biochemical studies. Hemoglobin (Hb g/dL), packed cell volume (PCV %), total leukocyte count (TLC cells/mm<sup>3</sup>), differential leukocyte count (DLC %) were recorded using Semi-automatic Haematological Analyser (MS39, Melet Schloesing Laboratories). The serum was collected after centrifugation of blood samples @3000 g for 5 min and stored at -20°C till further analysis. Blood glucose (mg/dL), blood urea nitrogen (BUN, mg/dL), creatinine (mg/dL), alkaline phosphatase (ALP, IU/L), alanine aminotransferase (ALT, IU/L), total protein (g/dL) albumin (g/dL) and globulin (g/dL) were estimated on Semi-automated Biochemistry Analyser (Systronics India Ltd.) following procedures and kits of Biolab Diagnostics.

The data were tabulated, and the mean and standard error were computed for all groups. Data were analyzed by using analysis of variance (ANOVA) as per the standard procedure. Statistically, significant difference was considered at 5 percent level.

## RESULTS AND DISCUSSION

### Effect of Treatment Regimens on Physiological Parameters

On day 0 rectal temperature was slightly elevated in Group II (102.6 ± 0.46) compared to normal physiological limits. The mean rectal temperature reduced gradually and returned to normal on day 8 following treatment protocols (Table 1). Statistically, the elevated temperature did not differ

significantly between days and groups. The mean heart rate in treatment groups before, during, and after treatment was within the normal physiological range (60–140 per minute) and did not differ significantly between days and groups. Bitches suffering from pyometra may also exhibit normal, subnormal, or elevated body temperature depending upon the severity of infection in the uterus (Jena *et al.*, 2013). Elevated body temperature was reported in bitches with pyometra by Kashi *et al.* (2009). The present findings on heart and the respiratory rate were in close agreement with the findings of Samantha *et al.* (2018).

### Effect of Treatment Regimens on Haematological Parameters

The mean values of hemoglobin concentration, packed cell volume (PCV), total leukocyte count (TLC), and differential leukocyte count (DLC) in bitches affected with pyometra in different groups on days 0, 4, and 8 of treatment are presented in Table 1. There was a significant ( $p < 0.05$ ) increase in the mean PCV in group II on day 8 over day 0. The hemoglobin level in clinically healthy bitches ranges from 12 to 18 g/dL (Schalm *et al.*, 1991 and Kochhar *et al.*, 1996). The lower mean hemoglobin values than the normal physiological levels suggest anemia in the pyometra-affected bitches (Greene, 2006 and Hadiya *et al.*, 2020). The post-treatment PCV values observed were within the normal physiological range (37–55%) and agreed with Jena *et al.* (2013).

On days 0 and 4, the mean leukocyte counts were significantly ( $p < 0.05$ ) higher in group II than group I (Table 1). The white blood cell count in clinically healthy and normal bitches varies between 6000–17000 cells/mm<sup>3</sup> (Schalm *et al.*, 1991). In the present study a marked leucocytosis recorded on day '0' was in accordance with the findings of Kochhar *et al.* (1996) and Jagyaseni (2016), which decreased significantly on day 8 of the treatment in both the groups. Leucocytosis as the most consistent finding among the bitches affected with pyometra has also been reported by Jena *et al.* (2013), Lakshmikanth *et al.* (2016), and Hadiya *et al.* (2020), suggestive of bone marrow inflammatory response and diffused suppurative inflammation of uterus to combat the infection.

On day 0 and 4 mean neutrophil count was significantly ( $p < 0.05$ ) higher yet within the normal physiological range (60–70%) in group II as compared to group I. The present findings were similar to the reports of Ravishankar *et al.* (2004), Jena *et al.* (2013), and Lakshmikanth *et al.* (2016). Neutrophilia observed in 100% of affected bitches might be due to retention of purulent exudates in the uterus, which exerts a chemotactic effect on neutrophils resulting in accelerated granulopoiesis (Mudasir *et al.*, 2011). On days 0 and 4, the mean lymphocyte percentage were significantly ( $p < 0.05$ ) higher in group I than in group II. Moreover, the pre-treatment lymphocyte count significantly increased on post-treatment days 4 and 8 in group II. The lymphocyte count was below the normal physiological range in the affected bitches.



**Table 1:** Effect of treatment (standard control and mifepristone) on physiological, hematological, and biochemical parameters of bitches affected with pyometra

Parameter	Groups	Day 0	Day 4	Day 8
<i>Physiological parameters</i>				
Temperature (°F)	Control	100.8 ± 0.13	100.4 ± 0.13	100.4 ± 0.13
	Mifepristone	102.6 ± 0.46	101.2 ± 0.26	101.0 ± 0.20
Heart rate (per min)	Control	78.0 ± 1.93	80.00 ± 1.93	77.0 ± 1.93
	Mifepristone	91.3 ± 8.74	81.50 ± 1.50	77.3 ± 5.33
Respiration rate (per min)	Control	36.0 ± 2.732	32.0 ± 2.732	32.0 ± 2.732
	Mifepristone	38.6 ± 5.86	36.0 ± 3.27	35.6 ± 2.67
<i>Haematological parameters</i>				
Haemoglobin (gm/dL)	Control	12.45 ± 0.36	12.50 ± 1.01	12.32 <sup>A</sup> ± 0.89
	Mifepristone	12.55 ± 1.07	13.30 ± 0.29	13.63 <sup>B</sup> ± 0.15
Packed Cell Volume (%)	Control	38.81 ± 0.760	39.63 ± 1.02	39.42 ± 0.96
	Mifepristone	33.66 <sup>a</sup> ± 1.73	36.58 <sup>ab</sup> ± 1.64	39.56 <sup>b</sup> ± 1.72
Total Leucocyte Count (Cells/mm <sup>3</sup> )	Control	12466.00 <sup>A</sup> ± 114	12183 <sup>A</sup> ± 116	12000 ± 1207
	Mifepristone	37850.00 <sup>Bb</sup> ± 712	24733 <sup>Bab</sup> ± 387	12500 <sup>a</sup> ± 1025
Neutrophils (%)	Control	73.00 <sup>A</sup> ± 1.63	71.50 <sup>A</sup> ± 1.68	71.16 ± 1.70
	Mifepristone	84.66 <sup>Bb</sup> ± 2.71	78.16 <sup>Bab</sup> ± 2.02	70.66 <sup>a</sup> ± 2.800
Lymphocyte (%)	Control	34.33 <sup>B</sup> ± 1.72	35.66 <sup>B</sup> ± 1.58	36.83 <sup>A</sup> ± 0.90
	Mifepristone	11.00 <sup>Aa</sup> ± 2.32	15.50 <sup>Aab</sup> ± 2.23	21.33 <sup>Bb</sup> ± 1.40
Monocyte (%)	Control	1.50 ± 0.22	1.51 <sup>A</sup> ± 0.22	1.16 <sup>A</sup> ± 0.16
	Mifepristone	2.50 ± 0.22	2.33 <sup>B</sup> ± 0.21	1.66 <sup>A</sup> ± 0.33
Eosinophil (%)	Control	1.66 <sup>A</sup> ± 0.33	1.83 ± 0.30	1.33 ± 0.21
	Mifepristone	2.16 <sup>B</sup> ± 0.83	2.16 ± 0.83	3.16 ± 1.47
<i>Biochemical parameters</i>				
Total Protein (g/dL)	Control	5.07 <sup>A</sup> ± 0.36	5.23 ± 0.26	5.02 ± 0.31
	Mifepristone	7.09 <sup>Bb</sup> ± 0.40	6.07 <sup>ab</sup> ± 0.36	5.26 <sup>a</sup> ± 0.35
Albumin (g/dL)	Control	3.78 ± 0.22	3.71 ± 0.23	3.66 ± 0.23
	Mifepristone	3.76 ± 0.46	3.85 ± 0.34	4.07 ± 0.28
Globulin (g/dL)	Control	2.28 <sup>A</sup> ± 0.40	2.30 ± 0.40	2.09 ± 0.36
	Mifepristone	3.32 <sup>Bb</sup> ± 0.50	2.22 <sup>ab</sup> ± 0.31	1.19 <sup>a</sup> ± 0.38
BUN (mg/dL)	Control	32.10 <sup>A</sup> ± 7.17	41.57 ± 4.83	41.57 ± 4.83
	Mifepristone	49.76 <sup>Bb</sup> ± 3.32	43.57 <sup>b</sup> ± 3.66	31.55 <sup>a</sup> ± 1.76
Creatinine (mg/dL)	Control	0.95 <sup>A</sup> ± 0.08	0.94 <sup>A</sup> ± 0.10	0.73 <sup>A</sup> ± 0.10
	Mifepristone	2.66 <sup>Bb</sup> ± 0.29	2.21 <sup>Bab</sup> ± 0.30	1.47 <sup>Ba</sup> ± 0.17
Glucose (mg/dL)	Control	93.44 ± 6.11	91.64 ± 5.52	89.74 ± 4.81
	Mifepristone	150.10 ± 27.49	127.98 ± 15.75	90.21 ± 14.3
ALT (U/L)	Control	41.57 ± 4.83	38.92 ± 3.88	37.28 ± 3.85
	Mifepristone	49.76 ± 3.32	43.57 ± 3.66	31.55 ± 1.76
Alkaline Phosphatase (U/L)	Control	69.19 ± 6.86	68.73 ± 6.59	67.56 ± 6.39
	Mifepristone	86.83 <sup>b</sup> ± 9.48	73.47 <sup>ab</sup> ± 9.41	46.75 <sup>a</sup> ± 7.70

Values bearing different superscripts (upper case between groups and lower case within the group) differ significantly from each other ( $p < 0.05$ ).

Lymphocytopenia was also reported in bitches with pyometra (Shah *et al.*, 2017) and may be due to an absolute increase in neutrophil count due to severe suppurative inflammation of the uterus. There was no significant difference between groups in mean monocyte and eosinophil count. The mean monocyte count was elevated than the normal bitches which is in accordance with the reports of Samantha *et al.* (2018). The significant increase in monocyte count may be attributed to chronic inflammatory responses. The eosinophil values were in close agreement with Jena *et al.*


(2013). However, lower eosinophils counts were reported by Ravishankar *et al.* (2004) and Lakshmikanth *et al.* (2016).

#### Effect of Treatment on Serum Biochemical Parameters

The mean serum total protein in the treatment groups varied significantly ( $p < 0.05$ ; Table 1) post-treatment compared to pre-treatment. The mean values recorded in the affected bitches were within the normal physiological range (5.3 to 7.6 mg/dL) and corroborated with the findings of Lakshmikanth *et al.*

(2016). Emanuelli *et al.* (2012) reported higher values of total protein. Hyperproteinaemia may be developed in pyometra-affected bitches due to dehydration (Verstegen *et al.*, 2008). Before treatment, the mean albumin level was slightly lower in group II compared to the normal physiological range but increased gradually to post-treatment. Hypoalbuminemia might be due to loss of albumin via the damaged kidneys and/or increased globulin production as a defense mechanism against infection (Singh *et al.*, 2020<sup>b</sup>). Ravishankar *et al.* (2004) reported hypoalbuminemia in pyometra cases with unchanged total plasma protein concentration. After treatment, the reduction in mean globulin level was significant ( $P < 0.05$ ; Table 1) in group II than in group I. The present finding of hyperglobulinemia in affected bitches found was in line with the report of Jena *et al.* (2013).

On day 0, the mean BUN value was significantly higher in group II than group I. Increased BUN levels in pyometra cases were observed, which then decreased following treatment. The present findings are in line with the findings of Shah *et al.* (2017) in pyometra-affected bitches. However, Jagyaseni (2016) recorded normal BUN levels in pyometra cases. There was a significantly ( $p < 0.05$ ) lower mean creatinine level in group II than group I. An increased BUN and serum creatinine levels can be associated with prerenal, renal, or post-renal causes (Ravishankar *et al.*, 2004). Similar pre-treatment findings were also recorded by Lakshmikanth *et al.* (2016) and Hadiya *et al.* (2020). Elevated serum creatinine might be due to organic tissue destruction or dehydrations (Mudasir *et al.*, 2011). Though glucose level was apparently higher in group II on days 0 and 4, there were no significant differences. No pertinent report on the effect of glucose in bitches affected with pyometra was found in the literature.



**Fig. 1:** Ultrasonographic images of the uterine horn of pyometra affected bitch. (A) Pre-treatment, increase echogenicity in the tubular horns, (B) Post-treatment, tubular horns filled with anechoic to hypoechoic area

**Table 2:** Post-treatment recovery of bitches affected with pyometra

Observations	Group I (Control)	Group II (Mifepristone)
No. of bitches treated	6	6
No. of bitches recovered	3	6
Recovery rate (%)	50	100
No. of bitches showed estrus	0	5
Recurrence of pyometra in bitches	2	1
Recurrence rate (%)	67	17

No significant difference was observed in the mean activity of ALT between groups on days 0, 4, and 8 (Table 1), and values were within the normal physiological range (10-94 U/L). These findings corroborated with the reports of Samantha *et al.* (2018). In group II, the mean ALP values were significantly ( $p < 0.05$ ) higher and reduced on days 4 and 8 over day 0. Similar findings were reported by Dabhi *et al.* (2007) and Shah *et al.* (2017). Three to four-fold increased plasma ALP activity was found in pyometric bitches due to damage to the vital organs and bone marrow associated with toxemia than healthy bitches (Hagman *et al.*, 2009).

### Post-Treatment Recovery Response of Bitches

The ultrasound examination post-treatment (Day 8) revealed a reduction in uterine lumen, the thickness of the uterine wall, and decreased echogenicity compared to day 0 indicative of treatment response (Fig. 1). These findings agreed with Samantha *et al.* (2018) and Singh *et al.* (2018). Recovery rate and recurrence rate in bitches of group I were recorded as 50% and 67%, respectively, as against 100% and 17% in group II (Table 2). The bitches ( $n = 3$ ) that did not recover within eight days of treatment were subjected to ovario-hysterectomy.

Bitches treated with progesterone receptor antagonist (mifepristone, group II) were cured entirely with a 100% recovery rate. Only one bitch showed recurrence of pyometra was subjected to ovario-hysterectomy. Fieni (2006) reported 84.4% and 83.33% recovery rates after using cloprostenol, which was higher than the present study. The present finding of recovery rate in the mifepristone-treated group was in close agreement with Shah *et al.* (2016). A lower recovery rate (50 to 83.3%) was also observed by Fieni (2006). Nevertheless, the success of treatment was associated with improved activity and appetite and an initial increase in vulvar discharge followed by diminished and serous discharge. Bitches treated with mifepristone showed some side effects like anorexia, excitation, vomiting, and diarrhea.

From the present findings, it could be concluded that mifepristone (progesterone receptor antagonist) proves to be a safe and efficient drug for opening the cervical canal in bitches. A combination with prostaglandin emerges as a new therapeutic possibility with a high success rate for the treatment of pyometra.

### ACKNOWLEDGEMENTS

Authors are highly thankful to the Dean, College of Veterinary Science and Animal Husbandry, Anjora, Durg, for providing necessary facilities.

### REFERENCES

Dabhi, D.M., Dhama, A.J., Tank, P.H., & Kelawala, N.H. (2007). Effect of ovario-hysterectomy on serum enzymatic and hormonal profile in bitches suffering from pyometra. *Indian Journal of Animal Reproduction*, 28(2), 1-6.





- Emanuelli, M.P., Martins, D.B., Wolkmer, P., Antoniazzi, A.Q., Emanuelli, T., de Vargas, A.C., & dos Anjos Lopes, S.T. (2012). Complete blood count, total plasma protein, neutrophil oxidative metabolism, and lipid peroxidation in female dogs with pyometra associated with *Escherichia coli*. *Comparative Clinical Pathology*, 21(3), 309-313.
- Fieni, F. (2006). Clinical evaluation of the use of aglepristone with or without cloprostenol, to treat cystic endometrial hyperplasia pyometra complex in bitches. *Theriogenology*, 66(6-7), 1550-1556.
- Greene, C.E. (2006). *Infectious Diseases of the Dog and Cat*. 3<sup>rd</sup> Edn., W. B. Saunders, Elsevier. p.1387.
- Hadiya, H.D., Patel, D.M., Parikh, P.V., & Rao Neha (2020). Haemato-biochemical studies before and after ovario-hysterectomy in bitches affected with pyometra. *The Indian Journal of Veterinary Sciences & Biotechnology*, 16(2): 45-49.
- Hagman, R., Reezigt, B.J., Ledin, H.B., & Karlstam, E. (2009). Blood lactate levels in 31 female dogs with pyometra. *Acta Veterinaria Scandinavica*, 51(1), 2.
- Hoffmann, B., Lemmer, W., Bosted, H., & Failing, K. (2000). Die Anwendung des Antigestagens Aglepristone zur konservativen Behandlung der Pyometra bei der Hundin. *Tierärztl Prax*, 28, 323-329.
- Jagyaseni, M. (2016). Cloprostenol and Cabergoline Therapy in Cystic Endometrial Hyperplasia pyometra Complex in the Bitches. *M.V.Sc Thesis*, Jawaharlal Nehru Krishi Vishwavidyalaya, Jabalpur, India.
- Jena, B., Rao, K.S., Reddy, K.C.S., & Raghavan, K.B.P. (2013). Comparative efficacy of various therapeutic protocols in the treatment of pyometra in bitches. *Veterinari Medicina*, 58(5), 271-276.
- Kashi, M., Tiwari, S.K., Sharda, R., Garg, S. & Kalim, M.O. (2009). Pyometra induced biochemical changes in bitches. *Indian Veterinary Journal*, 6(8), 853-855.
- Kochhar, H.P.S., Prabhakar, S., Gandotra, V.K., Rana, J.S., & Nanda, A.S. (1996). Chronic metritis and cystic endometrial hyperplasia along with bilateral uterine torsion in a bitch. *Indian Veterinary Journal*, 73(3), 326-329.
- Lakshmikanth, T.R., Murthy, V.C., Honnappa, T.G., Narayanaswamy, H.D., Rathnamma, & Kantharaj S. (2016). Physiological and hematobiochemical changes in open and closed pyometra in female dogs. *International Journal of Applied and Pure Science and Agriculture*, 2(3), 95-97.
- Melandri, M., Veronesi, M.C., Pisu, M.C., Majolino, G., & Alonge, S. (2019). Fertility outcome after medically treated pyometra in dogs. *Journal of Veterinary Science*, 20(4), e39.
- Mudasir, Q., Nema, S.P., Shukla, S.P., & Ali, R. (2011). Haemato-biochemical changes in pyometra affected bitches. *Veterinary Practitioner*, 12(1), 54-55.
- Noakes, D.E., Dhaliwal, G.K., & England, G.C. (2001). Cystic endometrial hyperplasia/pyometra in the dog: A review of the causes and pathogenesis. *Journal of Reproduction and Fertility* (Supplement), 57, 395-406.
- Ravishankar, N., Murlimanohar, B., Balachandran, C., Sumitra, M., Manikandan, P., & Puvanakrishnan, R. (2004). Haemato-biochemical alterations and pathological changes in canine pyometra. *Indian Journal of Veterinary Pathology*, 28(1), 14-17.
- Rootwelt-Andersen, V., & Farstad, W. (2006). Treatment of pyometra in the bitch: A survey among Norwegian small animal practitioners. *European Journal of Companion Animal Practice*, 16(2), 195-198.
- Samantha, G., Sarath, T., Monica, G., Arunmozhi, N., Sridevi, P., & Joseph, C. (2018). Ultrasonographic and haemato-biochemical evaluation of bitches affected with cystic endometrial hyperplasia-pyometra complex. *International Journal of Current Microbiology and Applied Science*, 7(6), 2327-2338.
- Schalm, O.W., Jain, N.C., & Caroll, E.D.J. (1991). Pyometra in dogs and regenerative shift to left in pyometra. In: *Veterinary Haematology*. 4<sup>th</sup> Edn. Lea and Febiger, 1051-1054, 1102-1104.
- Shah, M.A., Pande, N., Shah, I.A., Agrawal, R., Sharma, U., & Ghuman, S.P.S. (2016). Treatment of pyometra in female dogs using prostaglandin F<sub>2</sub>α plus antiprogestin (Mifepristone). *Indian Journal of Animal Reproduction*, 37(1), 23-26.
- Shah, S.A., Sood, N.K., Wani, B.M., Rather, M.A., Beigh, A.B., & Amin, U. (2017). Haemato-biochemical studies in canine pyometra. *Journal of Pharmacognosy and Phytochemistry*, 6(4), 14-17.
- Singh, L.K., Patra, M.K., Mishra, G.K., Saxena, A.C., De, U.K., Singh, S.K., Kumar, H., & Narayanan, K. (2020<sup>a</sup>). Prospects of diagnostic and prognostic biomarkers of pyometra in canine. *Asian Pacific Journal of Reproduction*, 9(4), 166-173.
- Singh, L.K., Patra, M.K., Mishra, G.K., Saxena, A.C., De, U.K., Singh, S.K., Kumar, H., & Narayanan, K. (2020<sup>b</sup>). Effect of systemic inflammatory response syndrome (SIRS) on prostaglandin metabolite and oxidative stress in canine pyometra. *Indian Journal of Animal Sciences*, 90(4), 569-573.
- Singh, L.K., Patra, M.K., Mishra, G.K., Singh, V., Upmanyu, V., Saxena, A.C., Singh, S.K., Das, G.K., Kumar, H., & Narayanan, K. (2018). Endometrial transcripts of proinflammatory cytokine and enzymes in prostaglandin synthesis are upregulated in the bitches with atropic pyometra. *Veterinary Immunology and Immunopathology*, 205, 65-71.
- Smith, F.O. (2006). Canine pyometra. *Theriogenology*, 66, 610-612.
- Verstegen, J., Dhaliwal, G., & Verstegen-Onclin, K. (2008). Mucometra, cystic endometrial hyperplasia, and pyometra in the bitch: Advances in treatment and assessment of future reproductive success. *Theriogenology*, 70(3), 364-374.